

# Dr Evangelia Tsapakis

General Adult Psychiatrist

BSc(Hons), MBBS, MSc, PhD(London), MRCPsych

GMC No. 4555054

Assistant Professor of Psychiatry, Aristotle University of Thessaloniki, Greece

3<sup>rd</sup> Department of Academic Psychiatry, AHEPA University General Hospital of Thessaloniki, Greece

Tel. 0030 6976114284; E: emtsapakis@doctors.org.uk

## DEGREES

- 1993 **BSc (Hons)** Pharmacology, King's College London, University of London, UK
- 1998 **MBBS**, St. George's Hospital Medical School, University of London, UK
- 2003 **DipCBT**, St. George's Hospital Medical School, University of London, UK
- 2003 **MRCPsych**, London, UK
- 2005 **Greek National Board Examinations in Psychiatry**, Greece
- 2006 **Certificate in Clinical Psychopharmacology**, British Association for Psychopharmacology, Cambridge, UK
- 2007 **MSc in Affective Neurosciences**, University of Maastricht, The Netherlands
- 2009 **PhD(London)**, Institute of Psychiatry, University of London, UK
- 2011 **CCCT in Psychiatry**, Specialist Register, General Medical Council No. 4555054, UK

## CLINICAL TRAINING

- 1999-2003 **SHO in General Adult Psychiatry** [St George's & Springfield University Hospitals, London, UK & The Maudsley & Royal Bethlem Hospitals, London, UK]
- 2003-2004 **Clinical & Research Fellow** [Harvard Medical School, McLean Hospital, Belmont, MA, USA]
- 2005-2011 **Hon Specialist Registrar in General Adult Psychiatry** [The Maudsley & Royal Bethlem Hospitals, London, UK]

## PAST EMPLOYMENT

- 2011-2023 **Clinical Director, AX Mental Health Clinic**, 71305 Heraklion, Crete, Greece; [www.axclinic.gr](http://www.axclinic.gr)

## PRIZES & AWARDS

- 1998 The Arthur Crisp Prize in Psychological Medicine, St. George's Hospital Medical School, University of London, UK
- 1998 The Michael Frowen Memorial Foundation Essay Prize for Medical Students, The Medical Council on Alcoholism, UK
- 2003 The 2003 Eli Lilly Travelling Fellowship, Royal College of Psychiatrists, London, UK
- 2004 Research Award (Special Mention), 5th International Neuropsychiatric Association Congress, Athens, Greece
- 2004 Special Individual Member, World Psychiatric Association
- 2005 Young Investigator Award, 20th International Congress on Schizophrenia Research, Savannah, USA
- 2007 Poster Award, 3rd International Congress on Brain & Behaviour, Thessaloniki, Greece

## CLINICAL RESEARCH GRANTS

### 2022-2025

**CONNEX III.** A phase III randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 10 mg once daily over 26-week treatment period in patients with schizophrenia; Sponsor: Boehringer- Ingelheim; Protocol No. 1346-0011 (PI)

### 2021-2022

**ESCAPE-TRD.** A Randomized, Open-label, Rater-Blinded, Active-Controlled, International, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Flexibly Dosed Esketamine Nasal Spray Compared With Quetiapine Extended- Release in Adult and Elderly Participants With Treatment-Resistant Major Depressive Disorder Who are Continuing a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor; Sponsor: Janssen – Cilag Greece; Protocol No. 54135419TRD3013; EUDRA-CT NO. 2019-002992-33 (PI).

### 2016-2017

**REMISSIO.** A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation In Patients with Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation Sponsor: Janssen – Cilag Greece; R092670SCH3015 (I)

### 2016-2017

**Paliperidone Palmitate Observational Study** A 12-Week, Prospective, Non-Investigational, Observation, Multicenter, Study in Greece in Young Patients with Schizophrenia Receiving Paliperidone Palmitate 1-Month Formulation; Sponsor: Janssen – Cilag Greece; R092670SCH4015 (I).

### 2014 -2018

**AXCT01-01-03-2013** A randomized, controlled trial of the effectiveness of add-on tolcapone to usual antipsychotic therapy on cognitive and negative symptoms of patients with schizophrenia genotyped for COMT polymorphisms. (EudraCT: 2013-

002713-35; Total Budget: 55.400,00€; Protocol Approval No. 9717/22-8-13 (PI).

#### 2013-2014

**HOSPIPalm** A Study of Usage of Paliperidone Palmitate in Patients With Schizophrenia in a Hospital Setting; Sponsor: JNJ; R092670SCH4017 (I).

#### 2012-2013

**ELPIS** An Observational Study of Depressive Symptom Prevalence and Demographics in Patients With Schizophrenia in Greece; Sponsor: Astra Zeneca; NIS-NGR-XXX-2012/1 (I).

#### 2011-2012

**MADDRE** An Observational Point Prevalence Study in Treatment-Resistant MDD; Sponsor: Astra Zeneca; NIS-NGR-XXX-2011/1 (I)

### SOCIETY MEMBERSHIPS

Royal College of Psychiatrists, London, UK (RCPsych), World Psychiatric Association (WPA), British Association for Psychopharmacology (BAP), Academy of Eating Disorders (AED), International Society for Psychiatric Genetics (ISPG), European College of Neuro- Psychopharmacology (ECNP), Hellenic Psychiatric Association (ΕΨΕ)

### PUBLICATIONS

#### Original Research Articles

1. Fountoulakis, K. N., Mitkani, C., Kyziridis, T., Panagiotidis, P., & **Tsapakis, E. M.** (2026). Factor Analysis of the Neurological Evaluation Scale (NES) and Corresponding Brain Function and Structures. *International journal of methods in psychiatric research*, 35(1), e70060. <https://doi.org/10.1002/mpr.70060>
2. Karakosta, E., **Tsapakis, E. M.**, Konsta, A., Lan, A., Einat, H., & Fountoulakis, K. N. (2026). Associations Among Binge Eating Behaviors, Emotion Regulation, and Chronotype in Female Greek University Students. *Current neuropharmacology*, 10.2174/011570159X431924251127110942. Advance online publication. <https://doi.org/10.2174/011570159X431924251127110942>
3. Koutra, E. P., Athanasiou, S., Karakosta, E., Arnaoutoglou, N., **Tsapakis, E. M.**, & Fountoulakis, K. N. (2025). Picture description impairment and neurocognition in schizophrenia: A pilot study. *Psychiatrike = Psychiatriki*, 36(3), 201–209. <https://doi.org/10.22365/jpsych.2025.011>
4. Souliotis, K., Golna, C., Samara, M., **Tsapakis, E. M.**, Bozikas, V. P., Hyphantis, T. N., Smyrnis, N., & Stefanis, N. (2025). Treatment-resistant or difficult-to-treat depression: a consensus on the pharmacotherapy challenges and considerations for the health care system in Greece. *Frontiers in psychiatry*, 16, 1561821. <https://doi.org/10.3389/fpsyt.2025.1561821>
5. Fountoulakis, K. N., Karakatsoulis, G., Abraham, S., Adorjan, K., Ahmed, H. U., Alarcón, R. D., Arai, K., Auwal, S. S., Berk, M., Levaj, S., Bobes, J., Bobes-Bascaran, T., Bourgin-Duchesnay, J., Bredicean, C. A., Bukelskis, L., Burkadze, A., Abud, I. I. C., Castilla-Puentes, R., Cetkovich, M., Colon-Rivera, H., ..., **Tsapakis, E. M.**, ..., Smirnova, D. (2025). Treatment and long-term outcome of mental disorders: The grim picture from a quasi-epidemiological investigation in 54,826 subjects from 40 countries. *Psychiatry research*, 348, 116459. <https://doi.org/10.1016/j.psychres.2025.116459>
6. Treiber, M. C.\*, **Tsapakis, E. M.**\*, Athanasiou, S., Chovardas, K., Kyziridis, T., & Fountoulakis, K. N. (2025). Neurological soft signs and thyroid hormones in schizophrenia spectrum disorders. *Progress in neuro-psychopharmacology & biological psychiatry*, 138, 111338. <https://doi.org/10.1016/j.pnpbp.2025.111338>
7. **Tsapakis, E.**, Paitaridou, D., Koummati, M., Chovardas, K., Fylaki, S., Karakatsoulis, G., & Fountoulakis, K. (2025). Manic symptoms in schizophrenia spectrum disorders. *Brain Medicine*, 1(2), 53–59. <https://doi.org/10.61373/bm025r.0005>
8. Treiber, M., **Tsapakis, E. M.**, & Fountoulakis, K. (2025). Repetitive Transcranial Magnetic Stimulation for Alcohol Craving in Alcohol Use Disorders: A Meta-analysis. *Journal of addiction medicine*, 19(2), 195–201. <https://doi.org/10.1097/ADM.0000000000001416>
9. Fountoulakis, K. N., Vrublevska, J., Abraham, S., ..., **Tsapakis E.M.**, ..., Smirnova, D. (2024). Non-binary gender, vulnerable populations and mental health during the COVID-19 pandemic: Data from the COVID-19 MEntal health inTernational for the general population (COMET-G) study. *Journal of affective disorders*, 352, 536–551. <https://doi.org/10.1016/j.jad.2024.02.050>
10. Fountoulakis, K. N., Karakatsoulis, G., Abraham, S., Adorjan, K., Ahmed, H. U., Alarcón, R. D., Arai, K., Auwal, S. S., Berk, M., Bjedov, S., Bobes, J., Bobes-Bascaran, T., Bourgin-Duchesnay, J., Bredicean, C. A., Bukelskis, L., Burkadze, A., Cabrera Abud, I. I., Castilla-Puentes, R., Cetkovich, M., Colon-Rivera, H., ..., **Tsapakis E.M.**, ..., Smirnova, D. (2024). Somatic multi-comorbidity and disability in patients with psychiatric disorders in comparison to the general population: a quasi-epidemiological investigation in 54,826 subjects from 40 countries (COMET-G study). *CNS spectrums*, 1–50. Advance online publication. <https://doi.org/10.1017/S1092852924000026>
11. Reif, A., Bitter, I., Buyze, J., Cebulla, K., Frey, R., Fu, D. J., Ito, T., Kambarov, Y., Llorca, P. M., Oliveira-Maia, A. J., Messer, T., Mulhern-Haughey, S., Rive, B., von Holt, C., Young, A. H., Godinov, Y., & **ESCAPE-TRD Investigators** (2023). Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression. *The New England Journal of Medicine*, 389(14), 1298–1309. <https://doi.org/10.1056/NEJMoa2304145>
12. Fountoulakis KN, Karakatsoulis G, Abraham S, ..., **Tsapakis EM**, ..., Smirnova D. Results of the COVID-19 mental health international for the health professionals (COMET-HP) study: depression, suicidal tendencies and conspiracism. *Soc*

Psychiatry Psychiatr Epidemiol. 2023 Mar 3:1–24.

13. Fountoulakis KN, Karakatsoulis GN, Abraham S, ..., **Tsapakis EM**, ..., Smirnova D. (2022) The effect of different degrees of lockdown and self-identified gender on anxiety, depression and suicidality during the COVID-19 pandemic: Data from the international COMET-G study. *Psychiatry Res*; 315: 114702.
14. Fountoulakis KN, Breda J, Arletto MP, Charalampakis AI, Karypidou MG, Kotorli KS, Koutsoudi CG, Ladia ES, Mitkani CA, Mpouri VN, Samara AC, Stravoravdi AS, Tsiamis IG, Tzortzi A, Vamvaka MA, Zacharopoulou CN, Prezerakos PE, Koupidis SA, K Fountoulakis N, **Tsapakis EM**, Konsta A, Theodorakis PN. (2022) Adherence to facemask use in public places during the autumn-winter 2020 COVID-19 lockdown in Greece: observational data. *Ann Gen Psychiatry*; 21: 9.
15. Fountoulakis KN, Apostolidou MK, Atsiova MB, Filippidou AK, Florou AK, Gousiou DS, Katsara AR, Mantzari SN, Padouva-Markoulaki M, Papatriantafyllou EI, Sacharidi PI, Tonia AI, Tsagalidou EG, Zymara VP, Prezerakos PE, Koupidis SA, Fountoulakis NK, Konsta A, **Tsapakis EM**, Theodorakis PN, Mossialos E. (2021) Mental health and conspiracism in health care professionals during the spring 2020 COVID-19 lockdown in Greece. *Acta Neuropsychiatr.*; 10: 1-16.
16. Fountoulakis KN, Karakatsoulis G, Abraham S, ..., **Tsapakis EM**, ..., Smirnova D. (2022) Results of the COVID-19 mental health international for the general population (COMET-G) study. *Eur Neuropsychopharmacol*; 54: 21-40.
17. Rantis K, Panagiotidis P, Parlapani E, Holeva V, **Tsapakis EM**, Diakogiannis I. (2021) Changes in alcohol, tobacco, cannabis use and gambling habits in the general population, during the Spring 2020 COVID-19 lockdown in Greece. *Journal of Substance Use*; DOI: 10.1080/14659891.2021.1941344.
18. Tsonis O, Diakaki K, Gkrozou F, Papadaki A, Dimitriou E, Paraskevidis M, Kyrgiou M, Paraskevidis E, Paschopoulos M, **Tsapakis EM**, Siafaka V. (2021) Psychological burden of covid-19 health crisis on health professionals and interventions to minimize the effect: what has history already taught us? *Riv Psichiatr*, 56: 57-63.
19. **Tsapakis EM**, Preti A, Mintzas MD, Fountoulakis KN. (2020) Adjunctive treatment with psychostimulants and stimulant-like drugs for resistant bipolar depression: a systematic review and meta-analysis. *CNS Spectr*. 9:1-31.
20. Nystazaki M, Pikouli K, **Tsapakis EM**, Karanikola M, Ploumpidis D, Alevizopoulos G. (2018) Decision-making Capacity for Treatment of Psychotic Patients on Long Acting Injectable Antipsychotic Treatment. *Arch Psychiatr Nurs*. 32:300-304.
21. Hargarter L, Lahaye M, Cherubin P, Lambert M, Swarz M, Joldygulov G, Vischia F, Chomskaya V, Bozikas VP, **Tsapakis EM**, Schreiner A. (2017) Safety, tolerability and treatment response with once-monthly paliperidone palmitate initiated shortly after hospital admission in patients with schizophrenia. *World Journal of Biological Psychiatry*, 8:1-11.
22. Roussos P, Giakoumaki SG, Zouraraki C, Fullard JF, Karagiorga VE, **Tsapakis EM**, Petraki Z, Siever LJ, Lencz T, Malhotra A, Spanaki C, Bitsios P. (2016) The Relationship of Common Risk Variants and Polygenic Risk for Schizophrenia to Sensorimotor Gating. *Biological Psychiatry*, 79:988-996.
23. Pasparakis E, Koiliari E, Zouraraki C, **Tsapakis EM**, Roussos P, Giakoumaki SG, Bitsios P. (2015) The effects of the CACNA1C rs1006737 A/G on affective startle modulation in healthy males. *European Psychiatry*, 30:492-498.
24. Nystazaki M, **Tsapakis EM**, Hadjulis M, Alevizopoulos G. (2014) Validation of the Glasgow Antipsychotic Side-Effect Scale (GASS) in Greece. *Journal of Psychology and Clinical Psychiatry*, 1(4): 00024.
25. Koola MM,\* **Tsapakis EM**\*, Wright P, Smith S, Kerwin RW (RIP), Nugent KL, Aitchison KJ. (2014) Association of Tardive Dyskinesia with Variation in CYP2D6: Is there a Role for Active Metabolites? *Journal of Psychopharmacology*, 28:665-670.
26. **Tsapakis EM**, Fernandes C, Moran-Gates T, Basu A, Sugden K, Aitchison KJ, Tarazi FI. (2014) Effects of antidepressant drug exposure on gene expression in the developing cerebral cortex. *Synapse*, 68: 209-220.
27. Giakoumaki SG\*, Roussos P\*, **Tsapakis EM**, Koiliari E, Pasparakis E, Zouraraki C, Bitsios P. (2013) Cognitive and personality analysis of startle reactivity in a large cohort of healthy males. *Biological Psychology*, 94: 582-591.
28. Giakoumaki SG, Roussos P, Zouraraki C, Spanoudakis E, Mavrikaki M, **Tsapakis EM**, Bitsios P. (2013) Sub-optimal parenting is associated with schizotypic and anxiety personality traits in adulthood. *European Psychiatry*, 28:254-260.
29. Fyndanis V, Manouilidou C, Koufou E, Karampekios S, **Tsapakis EM**. (2012) Agrammatic patterns in Alzheimer's disease: Evidence from tense, agreement, and aspect. *Aphasiology*, iFirst: 1-23
30. Aitchison KJ\*, **Tsapakis EM**\*, Huezo-Diaz P, Kerwin RW, Forsling ML, Wolff K. (2012) Ecstasy (MDMA)-induced hyponatraemia is associated with genetic variants in CYP2D6 and COMT. *Journal of Psychopharmacology*, 26:408-418.
31. Wolff K\*, **Tsapakis EM**\*, Pariante CM, Kerwin RW, Forsling ML, Aitchison KJ. (2012) Pharmacogenetic studies of change in cortisol on ecstasy (MDMA) consumption. [\*joint first authorship] *Journal of Psychopharmacology*, 26: 419-428.
32. **Tsapakis EM**, Tsiridis E, Hunter A, Gamie Z, Georgakarakos N, Thomas P, Schizas C, West RM. (2009) Modelling the effect of minor orthopaedic day surgery on patient mood at the early post-operative period: A prospective population-based cohort study. *European Psychiatry*, 24: 112-118.
33. Pattakou V, Adrachta T, **Tsapakis EM**, Markati I, Tsolaki M (2009) Late stage of patients with dementia in a nursing home in Greece. *Neurology* 18: 245-253.
34. **Tsapakis EM**, Soldani F, Tondo L, Baldessarini RJ (2008) Efficacy of antidepressants in juvenile depression: Ameta- analysis. *British Journal of Psychiatry*, 193, 10-17.
35. Wolff K, **Tsapakis EM**, Winstock AR, Hartley D, Holt D, Forsling ML, Aitchison KJ. (2006) Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population. *Journal of Psychopharmacology*, 20: 400-410.
36. Zhang K, Grady CJ, **Tsapakis EM**, Andersen SL, Tarazi F, Baldessarini RJ. (2004) Regulation of working memory by dopamine D4 receptors in the rat. *Neuropsychopharmacology*, 29:1648-1655.

## Review Articles

1. **Tsapakis, E.**, Karakosta, E., Karapatis, A., Papazoglou, A., Treiber, M., & Fountoulakis, K. N. (2025). The effects of neuromodulation interventions on the eating behaviors of patients with eating disorders compared to healthy controls, sham therapies, and other therapeutic approaches: A systematic review. *European psychiatry : the journal of the Association of European Psychiatrists*, 69(1), e5. <https://doi.org/10.1192/j.eurpsy.2025.10140>
2. **Tsapakis, E. M.**, Treiber, M., Mitkani, C., Drakaki, Z., Cholevas, A., Spanaki, C., & Fountoulakis, K. N. (2024). Pharmacological Treatments of Negative Symptoms in Schizophrenia-An Update. *Journal of clinical medicine*, 13(18), 5637. <https://doi.org/10.3390/jcm13185637>
3. **Tsapakis EM**, Diakaki K, Miliaras A, Fountoulakis K N (2023). Novel Compounds in the Treatment of Schizophrenia - A Selective Review. *Brain Sciences*, 13(8), 1193. <https://doi.org/10.3390/brainsci13081193>
4. **Tsapakis EM**, Mitkani CA, Fountoulakis KN. Neurological soft signs and schizophrenia. *CNS Spectr*. 2023 Mar 16:1-5.
5. Karakatsoulis GN, **Tsapakis EM**, Fountoulakis KN. (2021) [The role of ketamine in the treatment of treatment-resistant bipolar depression]. *Psychiatriki*; 32(Supplement I): 70-81. Greek, Modern.
6. Karakatsoulis GN, **Tsapakis EM**, Fountoulakis KN. (2021) [Clinical characteristics and treatment of treatment-resistant bipolar depression]. *Psychiatriki*; 32(Supplement I): 32-43. Greek, Modern.
7. Karakatsoulis GN, **Tsapakis EM**, Mitkani C, Fountoulakis KN. (2021) Subclinical thyroid dysfunction and major depressive disorder. *Hormones (Athens)*; 20: 613-621.
8. Downey CL, Young A, Burton EF, Graham SM, Macfarlane RJ, **Tsapakis EM**, Tsiridis E. (2017) Dementia and osteoporosis in a geriatric population: Is there a common link? *World Journal of Orthopaedics*, 8:412-423.
9. Dimopoulou T, Tarazi FI, **Tsapakis EM**. (2017) Clinical and therapeutic role of mentalization in schizophrenia-a review. *CNS Spectrums*, 21:1-13.
10. **Tsapakis EM**, Dimopoulou T, Tarazi FI. (2015) Clinical management of negative symptoms of schizophrenia: An update. *Pharmacology and Therapeutics*, 153:135-147.
11. Howgate DJ, Graham SM, Leonidou A, Korres N, Tsiridis E, **Tsapakis E**. (2013) Bone metabolism in anorexia nervosa: molecular pathways and current treatment modalities. *Osteoporosis International*, 24:407-421.
12. **Tsapakis EM**, Gamie Z, Tran GT, Adshead S, Lampard A, Mantalaris A, Tsiridis E. (2012) The adverse skeletal effects of selective serotonin reuptake inhibitors. *European Psychiatry*, 27, 156-169.
13. Graham SM, Howgate D, Anderson W, Howes C, Heliotis M, Mantalaris A, Tsiridis E, **Tsapakis E**. (2011) Risk of osteoporosis and fracture incidence in patients on antipsychotic medication. *Expert Opinion on Drug Safety*, 10, 575-602.
14. Baldessarini RJ, Pompili M, Tondo L, **Tsapakis EM**, Soldani F, Faedda GL, Hennen J. (2005) Antidepressants and suicidal behavior: Are we hurting or helping? *Clinical Neuropsychiatry*, 2: 1-3.
15. O'Daly OG, Guillin O, **Tsapakis EM**, Martinez D, Shegrill SS, Murray RM. (2005) Schizophrenia and substance abuse comorbidity: a role for dopamine sensitization? *Journal of Dual Diagnosis*, 1: 11-40.
16. **Tsapakis EM**, Basu A, Aitchison KJ. (2004) Transcriptomics and Proteomics: Advancing the Understanding of Psychiatric Pharmacogenomics. *Clinical Neuropsychiatry*, 1: 117-124.
17. **Tsapakis EM**, Basu A, Aitchison KJ. (2004) Clinical relevance of discoveries in psychopharmacogenetics. *Advances in Psychiatric Treatment*, 10: 455-465.
18. Basu A, **Tsapakis EM**, Aitchison KJ. (2004) Pharmacogenetics and psychiatry. *Current Psychiatry Reports*, 6: 134-142.
19. **Tsapakis EM** and Murray RM (2003) Is schizophrenia linked to long-term cannabis use? *Hospital Doctor*, 19<sup>th</sup> June.
20. **Tsapakis EM**, Guillin O, Murray RM (2003) Does dopamine sensitisation underlie the association between schizophrenia and substance abuse? *Current Opinion in Psychiatry*, 16 (Suppl. 2):S45-S52.
21. **Tsapakis EM** and Travis MJ (2002) Glutamate in Psychiatric Disorders. *Advances in Psychiatric Treatment*, 8(3): 189-197.
22. **Tsapakis EM** (2001) Genes lead to tailored therapy. *Progress in Neurology and Psychiatry*, 5(5): 12-14.

## Case Reports & Correspondence

1. Fountoulakis, K. N., & **Tsapakis, E. M.** (2024). Neither serotonin disorder is at the core of depression nor dopamine at the core of schizophrenia; still these are biologically based mental disorders. *Molecular psychiatry*, 29(1), 198–199. <https://doi.org/10.1038/s41380-024-02458-z>
2. Kenanidis E, Chrysovalantou Zagalioti S, Milonakis N, **Tsapakis EM**, Tsiridis E.(2020) A Catastrophic Cascade of Postoperative Complications Following Hemiarthroplasty for Femoral Neck Fracture in a Middle-Aged Patient With Schizophrenia. *Cureus* 12(7): e9044. DOI 10.7759/cureus.9044, accessed 17/07/2020.
3. Dimopoulou T and **Tsapakis EM**. (2014) The impact of economic crisis on drinking behaviours of adolescents and young adults in Greece. *European Journal of Public Health*, published January 28, <https://academic.oup.com/eurpub/article/24/3/410/475353>, accessed 17/07/2020 [letter].
4. **Tsapakis EM**, Soldani F, Tondo L, Baldessarini RJ. (2009) To prescribe or not to prescribe? *British Journal of Psychiatry*, 194, 189- 190 [letter]
5. Angoules A, **Tsapakis EM**, Polyzois I, Gamie Z, Rankine JJ, Tsiridis E. (2008) Cowden syndrome. Managing multiple

skeletal metastases of different origin: a case report. *Cases J.* 1:265.

6. Anand A, **Tsapakis EM**, Narvani AA, Alhakim A, Cannon SR, Tsiridis E. (2007) "Pseudosarcoma" in a pregnant woman. *World Journal of Surg Oncology*, 18: 5-7.
7. Vourliotaki I, Bonapart IE, Stamataki C, **Tsapakis EM**, Saridaki C. (2005) A case of a prolactinoma resistant to dopamine agonists. *Hormones*, 4: 165-170.
8. Tsiridis E, **Tsapakis EM**, Heliotis M, Donell ST, Scott DG. (2004) The Antiangiogenic Effect of Glioblastoma Multiforme Brain Tumor (Correspondence re: Morimoto et al., *Clin. Cancer Res.*, 8: 2933-2938, 2002). *Clinical Cancer Research*, 10:231-233.
9. Tsiridis E, Lusty PJ, Narvani AA, **Tsapakis EM** (2003) Doctors' knowledge of exposure to ionising radiation - Doctors' exposure to ionising radiation may be cause for concern. *British Medical Journal*, 327: 1167 [letter]

#### BOOK CHAPTERS

1. Dimopoulou T, Tarazi FI, **Tsapakis EM**. The clinical role of theory of mind in schizophrenia: A comprehensive review. In: *Schizophrenia, ebook*, Avid Science, Berlin, Germany, <https://www.avidscience.com/wp-content/uploads/2017/07/the-clinical-role-of-theory-of-mind-in-schizophrenia-a-comprehensive-review.pdf>, accessed 17/07/2020
2. **Tsapakis EM**, Curran S, Ohlsen RI, Vyas NS, Aitchison KJ, Daly A. Pharmacogenetics in psychiatry. In: *Pharmacogenomics and Individualized Therapy*, Maitland-van der Zee AH & Daly AK (eds.), John Wiley & Sons Inc., May 2012, pp. 215-250.
3. **Tsapakis EM** and Aitchison KJ. Biological Treatments: General Considerations. In: *Essential Psychiatry*, Murray R, Kendler KS, McGuffin P, Wessely S, Castle D (eds.), Cambridge University Press, September 2008; pp. 567-586.
4. Raznahan A, O'Daly OG, **Tsapakis EM**, Murray RM. Environmental determinants of psychosis. A focus on drug abuse. In: *Toward Prevention and Early Intervention of Major Mental and Substance Abuse Disorders*, Tsuang MT, Lyons MJ, Stone WS (eds.), American Psychiatric Publishing, Arlington, VA, 2007; pp. 21-53.

#### ACADEMIC EDITOR

*International Journal of Methods in Psychiatric Research*, Wiley [John Wiley & Sons, Inc.]

#### BOOK

**Tsapakis EM**. Travis MJ. Handbook of Schizophrenia. MCA, London, 2005

#### MONOGRAPHS

**Tsapakis E**. (1993) The effect of prodrugs of L-DOPA on the rotational behavior of 6-OHDA lesioned rats. BSc(Hons) in Pharmacology thesis.

**Tsapakis E**. (2007) Efficacy of antidepressants in juvenile depression: Meta-analysis and a Microarray Study in Rats. MSc in Affective Neurosciences thesis.

**Tsapakis E**. (2009) Pharmacogenetic and Pharmacogenomic Studies of the Effects of Psychotropic Agents. PhD thesis.

#### TEACHING EXPERIENCE

2004-2011	Lecturer, 4 <sup>th</sup> year medical student teaching in Psychiatry, School of Medicine, University of Crete, Greece
2017-present	Lecturer & Organizer, Neuropsychopharmacology Module (4 ECTS), MSc in Neurosciences, School of Medicine, University of Crete, Greece
2019-present	4 <sup>th</sup> -year and 6 <sup>th</sup> -year medical student teaching in Psychiatry, School of Medicine, Aristotle University of Thessaloniki, Greece
2019-present	Lecturer, MSc in Clinical Mental Health, School of Medicine, Aristotle University of Thessaloniki, Greece
2023-present	Responsible member of faculty for the undergraduate teaching of Psychiatry at the 3 <sup>rd</sup> Department of Academic Psychiatry, Aristotle University of Thessaloniki, Greece
2023-present	Lecturer & Organizer, Psychobiology of Behaviour (2 ECTS), an elective module for undergraduate medical students, Aristotle University of Thessaloniki, Greece
2023-present	Lecturer & Organizer, Introduction to Neurosciences (2 ECTS), an elective module for undergraduate medical students, Aristotle University of Thessaloniki, Greece

#### LANGUAGES

English (C2), Greek (native), French (C2)